학술논문
Real‐world efficacy of single‐agent belantamab mafodotin in relapsed systemic AL amyloidosis.
Document Type
Article
Author
Khwaja, Jahanzaib; Bomsztyk, Joshua; Atta, Maria; Bygrave, Ceri; Forbes, Adam; Durairaj, Senthil; Fernandes, Savio; Taylor, James; Paterson, Pamela; Brearton, Gillian; Crawley, Charles; Sheehy, Oonagh; Brown, Rachel; Soutar, Richard; Garg, Mamta; Rydzewski, Andrzej; Jamroziak, Krzysztof; Mahmood, Shameem; Wechalekar, Ashutosh D.
Source
Subject
*PLASMA cell diseases
*AMYLOIDOSIS
*ANTIBODY-drug conjugates
*
*
Language
ISSN
0007-1048
Abstract
Summary: Systemic light chain (AL) amyloidosis is a relapsing plasma cell disorder. Therapy is limited, particularly for triple‐class refractory disease. We report the use of belantamab mafodotin, a BCMA‐directed drug–antibody conjugate, for relapsed AL amyloidosis, including patients traditionally excluded from clinical trials. Thirty‐one patients were reviewed, with a median of three prior lines of therapy. The median follow‐up was 12 months (95% CI 4–19), and a median of five doses were delivered. The best haematological overall response rate was 71%, and the complete/very good partial response was 58%. Sixty‐eight percent had keratopathy and improved in all. Belantamab mafodotin has high efficacy and good tolerability in patients with relapsed AL amyloidosis. [ABSTRACT FROM AUTHOR]